Functional Interference in the Bone Marrow Microenvironment by Disseminated Breast Cancer Cells

Stem Cells

Volumn 34, Issue 8, 2016, Pages 2224-2235

  Dhawan, Abhishek ^a   von Bonin, Malte ^a,b,c   Bray, Laura J ^d,e   Freudenberg, Uwe ^d   Pishali Bejestani, Elham ^b,c   Werner, Carsten ^d   Hofbauer, Lorenz C ^a,b   Wobus, Manja ^a   Bornhäuser, Martin ^a,b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b German Consortium for Translational Cancer Research   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d LEIBNIZ INSTITUTE OF POLYMER RESEARCH DRESDEN   (Germany)

^e QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Basic fibroblast growth factor; Breast cancer; Hematopoietic stem and progenitor cells; HSPC engraftment; Mesenchymal stromal cells; Platelet derived growth factor

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR BB;

ARTICLE; BONE MARROW; BREAST CANCER; CANCER CELL; CELL DIFFERENTIATION; COCULTURE; CONTROLLED STUDY; DISSEMINATED CANCER; HUMAN; HUMAN CELL; LEUKAPHERESIS; MESENCHYMAL STROMA CELL; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84982793251     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2384     Document Type: Article

References (48)

1. Pantel K, Muller V, Auer M et al. Detection and clinical implications of early systemic tumor cell dissemination in breast cancer. Clin Cancer Res 2003;9:6326–6334.
2. Braun S, Kentenich C, Janni W et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 2000;18:80–86.
3. Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol 1983;23:175–180.
4. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s–6249s.
5. Weil RJ, Palmieri DC, Bronder JL et al. Breast cancer metastasis to the central nervous system. Am J Pathol 2005;167:913–920.
6. Mundy GR. Metastasis: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584–593.
7. Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature 2014;505:327–334.
8. Lo Celso C, Scadden DT. The haematopoietic stem cell niche at a glance. J Cell Sci 2011;124:3529–3535.
9. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006;6:93–106.
10. Calvi LM, Adams GB, Weibrecht KW et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003;425:841–846.
11. Zhang J, Niu C, Ye L et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003;425:836–841.
12. Shiozawa Y, Pedersen EA, Havens AM et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 2011;121:1298–1312.
13. Wobus M, List C, Dittrich T et al. Breast carcinoma cells modulate the chemoattractive activity of human bone marrow-derived mesenchymal stromal cells by interfering with CXCL12. Int J Cancer 2015;136::44−54.
14. Duryagina R, Thieme S, Anastassiadis K et al. Overexpression of Jagged-1 and its intracellular domain in human mesenchymal stromal cells differentially affect the interaction with hematopoietic stem and progenitor cells. Stem Cells Dev 2013;22:2736–2750.
15. Tsurkan M V, Chwalek K, Prokoph S et al. Defined polymer-peptide conjugates to form cell-instructive starPEG-Heparin matrices in situ. Adv Mater 2013;25:2606–2610.
16. Bray LJ, Binner M, Holzheu A et al. Multi-parametric hydrogels support 3D in vitro bioengineered microenvironment models of tumour angiogenesis. Biomaterials 2015;53:609–620.
17. Waskow C, Liu K, Darrasse-Jeze G et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol 2008;9:676–683.
18. Karajannis MA, Vincent L, DiRenzo R et al. Activation of FGFR1beta signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells. Leukemia 2006;20:979–986.
19. Acevedo VD, Ittmann M, Spencer DM. Paths of FGFR-driven tumorigenesis. Cell Cycle 2009;8:580–588.
20. Fierro FA, Kalomoiris S, Sondergaard CS et al. Effects on proliferation and differentiation of multipotent bone marrow stromal cells engineered to express growth factors for combined cell and gene therapy. Stem Cells 2011;29:1727–1737.
21. Coutu DL, Francois M, Galipeau J. Inhibition of cellular senescence by developmentally regulated FGF receptors in mesenchymal stem cells. Blood 2011;117:6801–6812.
22. Di Maggio N, Mehrkens A, Papadimitropoulos A et al. Fibroblast growth factor-2 maintains a niche-dependent population of self-renewing highly potent non-adherent mesenchymal progenitors through FGFR2c. Stem Cells 2012;30:1455–1464.
23. Xue Y, Lim S, Tang Y et al. PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat Med 2012;18:100–110.
24. Xie H, Cui Z, Wang L et al. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat Med 2014;20:1270–1278.
25. Moore DC, Ehrlich MG, McAllister SC et al. Recombinant human platelet-derived growth factor-BB augmentation of new-bone formation in a rat model of distraction osteogenesis. J Bone Joint Surg Am 2009;91:1973–1984.
26. Parmar K, Mauch P, Vergilio JA et al. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 2007;104:5431–5436.
27. Spencer JA, Ferraro F, Roussakis E et al. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature 2014;508:269–273.
28. Chow DC, Wenning LA, Miller WM et al.Modeling pO(2) distributions in the bone marrow hematopoietic compartment. I. Krogh's model. Biophys J 2001;81:675–684.
29. Chow DC, Wenning LA, Miller WM et al. Modeling pO(2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models. Biophys J 2001;81:685–696.
30. Eliasson P, Jonsson JI. The hematopoietic stem cell niche: low in oxygen but a nice place to be. J Cell Physiol 2010;222:17–22.
31. Caiado F, Carvalho T, Rosa I et al. Bone marrow-derived CD11b+Jagged2+ cells promote epithelial-to-mesenchymal transition and metastasization in colorectal cancer. Cancer Res 2013;73:4233–4246.
32. Karnoub AE, Dash AB, Vo AP et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557–563.
33. Jung Y, Kim JK, Shiozawa Y et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun 2013;4:1795.
34. Liu S, Ginestier C, Ou SJ et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011;71:614–624.
35. Fowler JA, Mundy GR, Lwin ST et al. Bone marrow stromal cells create a permissive microenvironment for myeloma development: A new stromal role for Wnt inhibitor Dkk1. Cancer Res 2012;72:2183–2189.
36. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003;17:1175–1182.
37. Bisping G, Leo R, Wenning D et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 2002;101:2775–2783.
38. Di Raimondo F, Azzaro MP, Palumbo G et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 2000;85:800–805.
39. Menzel T, Rahman Z, Calleja E et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 1996;87:1056–1063.
40. Cao XC, Zhang WR, Cao WF et al. Aquaporin3 is required for FGF-2-induced migration of human breast cancers. PLoS One 2013;8:e56735.
41. Chen J, Crawford R, Chen C et al. The key regulatory roles of the PI3K/Akt signaling pathway in the functionalities of mesenchymal stem cells and applications in tissue regeneration. Tissue Eng Part B Rev 2013;19:516–528.
42. Visnjic D, Kalajzic Z, Rowe DW et al. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood 2004;103:3258–3264.
43. Groen RWJ, Noort WA, Raymakers RA et al. Reconstructing the human hematopoietic niche in immunodeficient mice: Opportunities for studying primary multiple myeloma. Blood 2012;120:e9–e16.
44. Marlow R, Honeth G, Lombardi S et al. A novel model of dormancy for bone metastatic breast cancer cells. Cancer Res 2013;73:6886–6899.
45. Malanchi I, Santamaria-Martinez A, Susanto E et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012;481:85–89.
46. Xu S, Evans H, Buckle C et al. Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway. Leukemia 2012;26:2546–2549.
47. Bowers M, Zhang B, Ho Y et al. Osteoblast ablation reduces normal long-term hematopoietic stem cell self-renewal but accelerates leukemia development. Blood 2015;125:2678–2688.
48. Dhawan A, Friedrichs J, von Bonin M et al. Breast cancer cells compete with hematopoietic stem and progenitor cells for intercellular adhesion molecule-1 mediated binding to the bone marrow microenvironment. Carcinogenesis 2016 (in press).